Quince therapeutics to acquire erydel spa and its phase 3 asset targeting ataxia-telangiectasia with no currently approved treatments and estimated $1+ billion peak sales opportunity

South san francisco, calif.--(business wire)---- $qncx--quince therapeutics, inc. (nasdaq: qncx), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that the company has entered into an agreement to acquire erydel spa, a privately-held, late-stage biotech company, in a stock-for-stock upfront exchange and potential downstream milestone cash payments. erydel has developed an autologous intracellular drug enc.
QNCX Ratings Summary
QNCX Quant Ranking